FTC Tells Medtronic To Sell Intersect ENT Subsidiary To Avoid Monopoly

The move removes all regulatory roadblocks to Medtronic’s $1.1bn acquisition of Intersect ENT, which was announced in August 2021.

FTC building, Washinton, DC / USA - April 22 2019: The north facade of the Federal Trade Commission building with carved sculpture above an enterence.
• Source: Shutterstock

More from Regulation

More from Policy & Regulation